((自动化翻译由路透提供，请见免责声明 )) Anirban Sen
路透纽约1月6日 - 熟悉内情的人士周一告诉路透，医疗设备制造商史赛克 正在就收购Inari Medical 进行深入谈判。
这些消息人士说，如果谈判成功，最快本周就会宣布交易，但他们要求匿名，因为讨论是保密的。
对市值近30亿美元的Inari公司的收购将有助于史赛克扩大其产品线，以治疗一种被称为静脉血栓栓塞症的血脉凝结疾病和其他静脉疾病。
消息人士称，在收到史赛克和其他各方的收购意向后，Inari公司最近几周一直在与顾问合作探讨出售事宜，但他们提醒说，可能会有另一家收购方与Inari公司接触，也有可能不会与任何一方达成交易。
史赛克和伊纳里没有立即回应置评请求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.